DuChemBIO Co.,Ltd.
Financials
Valuation Metrics
DuChemBIO Co.,Ltd.'s Market Cap is ₩1726B. At end of 2025 it was ₩2712B. Ranked #937 of 2,421 in KR market (top 39%), #453 of 1,640 on KOSDAQ (top 28%), #29 of 96 in Health Care Equipment & Services (top 30%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 172.64B KRW | KR#937/2,421 Sec#29/96 |
| Revenue | 41.51B KRW | KR#1,902/2,421 Sec#54/96 |
| Net Income | 6.83B KRW | KR#1,095/2,421 Sec#33/96 |
| Total Assets | 77.60B KRW | KR#1,952/2,421 Sec#64/96 |
| Net Assets | 51.57B KRW | KR#1,887/2,421 Sec#59/96 |
| Employees | 141 | KR#1,369/2,421 Sec#46/96 |
| Value | ||
| P/E | 25.29x | KR#1,255/2,421 Sec#42/96 |
| P/B | 3.35x | KR#2,138/2,421 Sec#78/96 |
| P/S | 4.16x | KR#2,089/2,421 Sec#69/96 |
| EV/EBITDA | 19.75x | KR#1,008/2,421 Sec#33/96 |
| FCF Yield | 5.26% | KR#832/2,421 Sec#20/96 |
| Profitability | ||
| ROE | 13.24% | KR#405/2,421 Sec#16/96 |
| ROA | 8.80% | KR#360/2,421 Sec#20/96 |
| Op. Margin | 19.45% | KR#173/2,421 Sec#13/96 |
| Revenue Growth | 8.35% | KR#995/2,421 Sec#56/96 |
| Earnings Growth | -18.94% | KR#924/2,421 Sec#36/96 |
| Financial Health | ||
| Debt Ratio | 50.47% | KR#962/2,421 Sec#54/96 |
| Total Debt | 5.86B KRW | KR#1,760/2,421 Sec#64/96 |
| FCF | 9.07B KRW | KR#738/2,421 Sec#19/96 |
| Cash | 19.03B KRW | KR#1,274/2,421 Sec#36/96 |
| Current Ratio | 1.80x | KR#975/2,421 Sec#58/96 |
| Net Debt/EBITDA | -1.63x | KR#277/2,421 Sec#7/96 |
| Performance | ||
| 1Y Return | -39.94% | KR#1,827/2,421 Sec#59/96 |
| 1M Return | -6.19% | KR#1,879/2,421 Sec#62/96 |
| From 52W High | -52.55% | KR#1,511/2,421 Sec#47/96 |
| 1Y MDD | -53.42% | KR#1,145/2,421 Sec#39/96 |
| Trading | ||
| Volume | 15,882 shares | KR#1,704/2,421 Sec#64/96 |
| Trading Value | 96.3M KRW | KR#1,574/2,421 Sec#64/96 |
| Foreign Own. | 0.81% | KR#2,106/2,421 Sec#82/96 |
| Per Share | ||
| EPS | 240 KRW | KR#1,239/2,421 Sec#37/96 |
| BPS | 1,810 KRW | KR#2,104/2,421 Sec#72/96 |
Company Info
DuChemBio was established in 2002 for the development, manufacturing, and sales of radiopharmaceuticals for cancer and brain disease diagnosis and treatment, completing its KOSDAQ transfer listing in 2024. The company holds the largest number of PET-CT pharmaceuticals in Korea and operates 12 GMP-certified manufacturing facilities, achieving the top market share in major product categories. With a "First-in-Class" strategy for diagnostics and "Best-in-Class" for therapeutics, DuChemBio is striving to become a specialized radiopharmaceutical platform company in Asia. DuChemBio was established in 2002 and is headquartered in Mapo-gu, Seoul.